10 Best Promising Stocks To Invest In 2014

Onyx Pharmaceuticals (NASDAQ: ONXX  ) is having a garage sale, but it doesn't appear that Amgen (NASDAQ: AMGN  ) has been invited.

The promising cancer developer confirmed over the weekend that Amgen had made an offer to acquire Onyx for $120 per share, a 38.2% premium above Friday's close. Onyx certainly didn't waste any time rejecting the bid, commenting that it "significantly undervalued Onyx and its prospects, and was not in the best interest of Onyx or its shareholders." That hasn't, however, stopped Onyx from actively engaging in additional acquisition chatter with other interested parties outside of Amgen.

The interest in Onyx will come down to two big questions: How much is it worth considering that it only receives a percentage of net sales on two of its three cancer drugs? And who might the buyer be?

How Onyx makes its money
The first question, as I've noted, is quite tricky.

Nexavar, the company's most mature cancer drug, is currently approved by the Food and Drug Administration to treat the most common forms of kidney and liver cancer. Aside from Japan, though, it splits the profits of Nexavar with licensing partner Bayer�down the middle. There's also a strong possibility that Nexavar could be in line for an added indication in treating thyroid cancer based on the extended progression-free survival it delivered relative to the placebo in a late-stage trial.

Hot Communications Equipment Companies To Own For 2015: Enertopia Corp (ENRT)

Enertopia Corp (Enertopia), incorporated on November 24, 2004, is engaged in medicinal marijuana business. The Company is diverse in its pursuit of business opportunities in several sectors, including: Medicinal Marijuana, Oil and Gas, Solar PV (Photovoltaic), Solar Thermal (Hot Water), Energy Retrofits and Recovery, and Solar powered Filtered Drinking Water.

The Company no longer has any material oil and gas resources. The Company operates in two segments: renewable energy, and mining exploration and developments, which are managed separately based on fundamental differences in their operations nature.

Advisors' Opinion:

• [By Peter Graham]

  What�� the Catch With Lexaria Corp? According to various disclosures, a transaction or transactions of $1k has or will occur to mention Lexaria Corp in various investment newsletters. Last Friday, Lexaria Corp announced it had closed its Private Placement financing announced on March 5 for gross proceeds of $1,272,000 ��higher than the originally announced $960,000 figure due to ��verwhelming demand.��Lexaria Corp will issue 10,600,000 common shares at US$0.12 and 10,600,000 full warrants that expire on September 21, 2016 with an exercise price of US$0.25. However, the company may also accelerate the expiry date of the warrants if the stock price trades above CAD$0.40 cents for 20 consecutive days at any time after 6 months and one day has elapsed. Otherwise and in early March, Lexaria Corp reported that its board of directors had decided to make a strategic entry into the medical marijuana business by way of an ��mportant Joint Venture��with Enertopia Corp (OTCQB: ENRT). Under the terms of the Agreement, Lexaria Corp had agreed to pay Enertopia 1 million restricted common shares in return for Enertopia's participation plus 500,000 restricted common shares ENRT�� Chairman in return for his participation on the Lexaria Advisory Board. Following the issuance of these shares, Lexaria Corp will have a total of 18,431,452 shares issued and outstanding and 21,256,452 shares fully diluted. A quick look at Lexaria Corp�� financials reveals revenues of $160k (most recent reported quarter), $241k, $251k and $253k for the past four quarters along with net losses of $102k (most recent reported quarter), $126k, $58k and $48k. At the end of last January, Lexaria Corp had $66k in cash to cover $1,415k in current liabilities and $59k in other liabilities. So aside from the income statement, investors might want to look more closely at Lexaria Corp�� financing terms.

10 Best Promising Stocks To Invest In 2014: Sensio Technologies Inc (PSN)

SENSIO Technologies Inc. (SENSIO) develops and markets stereoscopic technologies for the electronic consumer, digital broadcasting and digital cinema markets. The Company focuses on three dimensional (3D) video, develops and markets stereoscopic (3D) digital compression, decompression, and display-formatting technologies. Its solutions include content creators, games developers, broadcasters, specialty channels and digital cinemas. Its flagship technology, SENSIO 3D, allows distribution of 3D content through conventional two dimensional (2D) broadcast networks (cable, satellite, Internet Protocol) and playback on any 3D display device, as well as home theatre and digital cinema projectors. The Company operates in North America, Europe, Middle East and Oceania. Advisors' Opinion:

• [By Inyoung Hwang]

  Bovis Homes Group Plc (BVS) climbed 4 percent to 790 pence. Liberum Capital Ltd. raised its rating on the housebuilder to buy from hold. Persimmon Plc (PSN), the U.K.�� largest residential property developer, gained 2.5 percent to 1,255 pence.

• [By Sofia Horta e Costa]

  Countrywide Plc dropped 4.9 percent as Alchemy Partners LLP sold a 5.9 percent stake in the real estate broker. A gauge of London-listed mining stocks fell 1.7 percent, paring its best quarter since 2010. Persimmon Plc (PSN) led housebuilders lower after the U.K. government said it will carry out annual checks on its home-buying-assistance program amid criticism it may lead to excessive real estate prices.

10 Best Promising Stocks To Invest In 2014: The Finish Line Inc.(FINL)

The Finish Line, Inc., together with its subsidiaries, operates as a mall-based specialty retailer in the United States. It operates Finish Line stores that offer performance and athletic casual footwear, apparel, and accessories for men, women, and kids. The company also sells merchandise through its Web site, finishline.com. As of September 22, 2011, it operated 646 stores in the United States. The company was founded in 1976 and is headquartered in Indianapolis, Indiana.

Advisors' Opinion:

• [By Shauna O'Brien]

  Shares of Finish Line Inc (FINL) were up nearly 6% on Friday morning after the company reported better than expected third quarter results and raised its FY2014 outlook.

  FINL’s Earnings in Brief

  -FINL reported Q3 earnings of $2.32 million, compared to a a loss of $0.11 million a year ago. On a per share basis, earnings were 5 cents per share.

  -On a Non-GAAP basis, EPS came in at 6 cents, 5 cents above analysts’ estimate of 1 cent.

  -Revenue for the quarter rose to $364.5 million, up from $296.62 million last year. Analysts expected to see revenue of $354.57 million.

  -Comparable store sales increased 7.1% during the quarter.

  -Looking ahead, FINL has raised its outlook for FY2014 and now sees earnings between $1.60 and $1.65 per share. Analysts expect to see earnings of $1.59 per share.

  CEO Commentary
  Chairman and CEO, Glenn Lyon commented: “We are very pleased with the top and bottom line performance we delivered in the third quarter.�Our commitment to developing a premier omni-channel platform is strengthening both our customer relationships and our brand partnerships while also reinforcing our market leadership position. We are continually adapting and refining our strategies in this rapidly evolving retail landscape to ensure we meet the needs of today’s empowered consumer. Finish Line is on the right strategic course and is well-positioned to deliver on our near and longer term goals.”

  FINL’s Dividend
  FINL made no mention of when its next quarterly dividend will be, as the company just paid a 7 cent dividend on December 16. However, it is likely that FINL will announce a 1 cent dividend increase in January.

  Stock Performance
  Finish Line shares were up $1.54, or 5.89%, during pre-market trading Friday. The stock is up 38% YTD.

10 Best Promising Stocks To Invest In 2014: Arabian American Development Co (ARSD)

Arabian American Development Company, incorporated in 1967, is engaged in manufacturing various specialty petrochemical products. As of December 31, 2011, the Company owned a 37% interest in Al Masane Al Kobra Mining Company and a 55% interest in Pioche Ely Valley Mines, Inc (PEVM). The Company�� United States activities are primarily conducted through a wholly owned subsidiary, Texas Oil and Chemical Co. II, Inc. (TOCCO). TOCCO owns of South Hampton Resources Inc. (South Hampton), and South Hampton owns of Gulf State Pipe Line Company, Inc. (Gulf State).

South Hampton owns and operates a specialty petrochemical facility near Silsbee, Texas, which produces petrochemical solvents and other petroleum based products, including isopentane, normal pentane, isohexane and hexane, which is used in the production of polyethylene, packaging, polypropylene, expandable polystyrene, poly-iso/urethane foams, and in the catalyst support industry. Gulf State owns and operates three pipelines that connect the South Hampton facility to a natural gas line, to South Hampton�� truck and rail loading terminal and to a petroleum products pipeline owned by an unaffiliated third party.

South Hampton owns and operates a specialty petrochemical facility near Silsbee, Texas which is approximately 30 miles north of Beaumont, Texas, and 90 miles east of Houston. The facility consists of seven operating units which, while interconnected, make distinct products through differing processes: a Penhex Unit; a Reformer; a Cyclo-pentane Unit; an Aromax Unit; an Aromatics Hydrogenation Unit; a White Oil Fractionation Unit, and a Hydrocarbon Processing Demonstration Unit.

Gulf State owns and operates three 8-inch diameter pipelines aggregating approximately 50 miles in length connecting South Hampton�� facility to: a natural gas line, South Hampton�� truck and rail loading terminal and a petroleum products pipeline system owned by an unaffiliated third party. The Penhex Unit has the capacity! to process approximately 6,700 barrels per day, with the Reforming Unit, the Aromax Unit, and the Cyclo-Pentane Unit further processing streams produced by the Penhex Unit. The Aromatics Hydrogenation Unit has a capacity of approximately 400 barrels per day, and the White Oils Fractionation Unit has a capacity of approximately 3,000 barrels per day. The Hydrocarbon Processing Demonstration Unit has a capacity of approximately 300 gallons per day. The facility generally consists of equipment commonly found in petrochemical facilities, such as fractionation towers and hydrogen treaters except the facility is adapted to produce specialized products. South Hampton produces eight distinct product streams and markets several combinations of blends as needed in various customers��applications.

The Reformer and Aromax units are operated as needed to support the Penhex and Cyclo-pentane Units. The other two operating units at the plant site, an Aromatics Hydrogenation Unit and a White Oils Fractionation Unit, are operated as two, independent and completely segregated processes. These units are dedicated to the needs of two different toll processing customers. Products may be sold directly from South Hampton�� storage tanks or transported to the customers��location for storage and marketing. South Hampton, in support of the petrochemical operation, owns approximately 75 storage tanks with total capacity approaching 225,000 barrels, and 95 acres of land at the plant site, 55 acres of which are developed. South Hampton also owns a truck and railroad loading terminal consisting of storage tanks, four rail spurs, and truck and tank car loading facilities on approximately 53 acres of which 13 acres are developed.

The Company�� mineral interest in the United States is its 55% ownership interest in an inactive corporation, PEVM. PEVM�� properties include 48 patented and 5 unpatented claims totaling approximately 1,500 acres. All of the claims are located in Lincoln County, Nevada.

Advisors' Opinion:

• [By Seth Jayson]

  Arabian American Development (NYSE: ARSD  ) reported earnings on June 26. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q1), Arabian American Development beat expectations on revenues and beat expectations on earnings per share.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Arabian American Development (NYSE: ARSD  ) , whose recent revenue and earnings are plotted below.

10 Best Promising Stocks To Invest In 2014: Amyris Inc.(AMRS)

Amyris, Inc., an integrated renewable products company, provides alternatives to a range of petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide. The company uses its industrial synthetic biology platform to modify microorganisms, primarily yeast, to convert plant-sourced sugars into a variety of hydrocarbon molecules that serve as flexible building blocks to be used in a range of products. It is also involved in the sale of ethanol and ethanol blended gasoline to wholesale customers through a network of terminals primarily in the southeastern Unites States. In addition, the company sells farnesene or Biofene, which is used as an ingredient in a range of consumer and industrial products, including detergents, cosmetics, perfumes, and industrial lubricants. Further, it focuses on the commercialization of renewable diesel and jet fuel. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc . in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

Advisors' Opinion:

• [By Maxx Chatsko]

  Renewable oils manufacturer Solazyme (NASDAQ: SZYM  ) got walloped after announcing a new commercialization strategy that will result in drastically reduced production volumes from facilities in Clinton, Iowa and Moema, Brazil and less revenue in 2015 and beyond than originally expected. The company's former commercialization strategy of selling massive volumes of commodity replacements relied on optimized, low-cost production and numerous customers. That stood in contrast to the strategy settled into by fellow industrial biotech Amyris (NASDAQ: AMRS  ) at the end of 2012, which relied on producing low volumes of high value products, seeding important long-term markets, driving costs down with new microbial production strains, and adopting an efficient corporate cost structure.

• [By Maxx Chatsko]

  I imagine the company has made headway since its initial press release, especially with commissioning for its Moema, Brazil, biorefinery looming. When updates are given on commercial achievements in the months ahead, will you be able to digest the important information that affects your investments? Heading into the homestretch of the first wave of commercial buildout, it is crucially important to understand what Solazyme, Gevo (NASDAQ: GEVO  ) , and�Amyris� (NASDAQ: AMRS  ) spill in press releases -- and the greater detail given in SEC filings.

10 Best Promising Stocks To Invest In 2014: Baxter International Inc. (BAX)

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. It operates in three segments: BioScience, Medication Delivery, and Renal. The BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and vaccines. The Medication Delivery segment manufactures intravenous solutions and administration sets; premixed drugs and drug-reconstitution systems; pre-filled vials and syringes for injectable drugs; intravenous nutrition products; infusion pumps; and inhalation anesthetics. It also offers products and services related to pha rmacy compounding, drug formulation, and packaging technologies. The Renal segment provides products to treat end-stage renal disease or irreversible kidney failure. It manufactures solutions and other products for peritoneal dialysis, a home-based therapy; and distributes product for hemodialysis, which is conducted in a hospital or clinic. It markets its products to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors? offices, clinical and medical research laboratories, and patients at home under physician supervision. The company was founded in 1931 and is based in Deerfield, Illinois.

Advisors' Opinion:

• [By Jayson Derrick]

  Pfizer (NYSE: PFE) has agreed to acquire Baxter International's (NYSE: BAX) vaccine business for $635 million. Shares of Pfizer lost 0.71 percent, closing at $29.26 while shares of Baxter International lost 0.33 percent, closing at $76.09.

• [By Jon C. Ogg]

  Baxter International Inc. (NYSE: BAX) was downgraded to Neutral from Outperform at Credit Suisse based on earnings uncertainty around its competitive long-acting recombinant franchise.

10 Best Promising Stocks To Invest In 2014: Molson Coors Brewing Company(TAP)

Molson Coors Brewing Company brews, markets, sells, and distributes beer brands. It sells its products in Canada, under the Coors Light, Molson, Rickard's Red, Carling, Pilsner, Keystone Light, Creemore Springs, and Granville Island brands. The company also brews or distributes products under license from third parties, which include Heineken, Amstel Light, Murphy's, Asahi, Asahi Select, Miller Lite, Miller Genuine Draft, Miller Chill, Milwaukee's Best, Milwaukee's Best Dry, and Foster's. In addition, it imports, distributes, and markets the Corona, Coronita, Negra Modelo, and Pacifico brands, through a joint venture agreement with Grupo Modelo. Further, the company sells various brands in the United States, which include Coors Light, Miller Lite, Coors Banquet, Miller Genuine Draft, MGD 64, Miller Chill, Sparks, Miller High Life, Miller High Life Light, Keystone Light, Icehouse, Mickey's, Milwaukee's Best, Milwaukee's Best Light, Old English 800, Blue Moon, Henry Weinhard 's, George Killian's Irish Red, Leinenkugel's, Peroni Nastro Azzurro, Pilsner Urquell, Grolsch, Coors Non-Alcoholic, and Sharp's. Additionally, it sells various brands in the United Kingdom comprising Carling, C2, Coors Light, Worthington's, White Shield, Caffrey's, Kasteel Cru, and Blue Moon, as well as various regional ale brands. The company also sells the Grolsch brands through a joint venture with Royal Grolsch N.V. and the Cobra brands through a joint venture called Cobra Beer Partnership Ltd.; and distributes brands sold under license, including Corona, Coronita, Negra Modelo, Pacfico, Singha, and Magners Draught Cider. In addition, it markets and sells Zima, Si'hai, Coors Gold, and Coors Extra brands to various international markets. The company was formerly known as Adolph Coors Company and changed its name to Molson Coors Brewing Company as a result of its merger with Molson Inc. in February 2005. Molson Coors Brewing Company was founded in 1873 and is headquartere d in Denver, Colorado.

Advisors' Opinion:

• [By Sean Williams]

  As the owner of both hard liquor and beer lines, Diageo must split its focus along two fronts. In spirits it must grapple against its two primary foes, Brown-Forman� (NYSE: BF-B  ) , maker of Jack Daniel's and Southern Comfort, and Beam (NYSE: BEAM  ) , which (surprise, surprise!) makes Jim Beam, as well as Maker's Mark and other brands of spirits. In beer, it goes up against domestic and global giants like Anheuser-Busch InBev (NYSE: BUD  ) and Molson Coors (NYSE: TAP  ) .

• [By Lauren Pollock]

  Molson Coors Brewing Co.'s(TAP) third-quarter earnings fell 39% as the beer company’s results were hurt by a write-down tied to two European brands and revenue weakened slightly. Results were mixed as the bottom line beat views and the top line missed. Shares edged up 1.8% to $55 in light premarket trading.

• [By Jonas Elmerraji]

  Molson Coors Brewing (TAP) operates in a different corner of the alcoholic beverage business: beer. The $9 billion brewer is one of the biggest in the world, with brands like Molson and Coors as well as Blue Moon, Keystone and Miller Lite (the latter through a joint venture with SABMiller (SBMRY: Pink Sheets) here in the U.S.).

  Molson Coors is engaged in a battle of the big boys – as the second largest brewer in Canada and the U.S., the firm primarily competes against top-rival Anheuser Busch Inbev (BUD) for market share. Like BEAM with its small barrel bourbon line, TAP has poured resources into the craft beer segment, the fastest-growing area in the alcoholic beverage space. While that's not likely to materially change its business, it should provide a welcome margin boost.

  Beer sales tend to ebb and flow with the broad economy. In 2013, with consumer discretionary spending on the upswing, beer spending should grow in kind. For TAP specifically, the possibility of a falling dollar bodes well for the firm's large international exposure -- and its ability to hike its payout.

  Right now, TAP pays a 32-cent dividend for a 2.6% yield.